Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-27T19:34:34.492Z Has data issue: false hasContentIssue false
  • English
  • Français

WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults

Published online by Cambridge University Press:  07 November 2014

John H. Greist ,
Borwin Bandelow ,
Eric Hollander ,
Donatella Marazziti ,
Stuart A. Montgomery ,
David J. Nutt ,
Ahmed Okasha ,
Richard P. Swinson  and
Joseph Zohar
Get access Rights & Permissions [Opens in a new window]

Abstract

What are the latest psychotherapeutic and pharmacotherapeutic treatment recommendations for obsessive-compulsive disorder (OCD)? OCD is a relatively common disorder with a lifetime prevalence of ~2% in the general population. It often has an early onset, usually in childhood or adolescence, and frequently becomes chronic and disabling if left untreated. High associated healthcare utilization and costs, and reduced productivity resulting in loss of earning, pose a huge economic burden to OCD patients and their families, employers, and society. OCD is characterized by the presence of obsessions and compulsions that are time-consuming, cause marked distress, or significantly interfere with a person's functioning. Most patients with OCD experience symptoms throughout their lives and benefit from long-term treatment. Both psychotherapy and pharmacotherapy are recommended, either alone or in combination, for the treatment of OCD. Cognitive-behavioral therapy is the psychotherapy of choice. Pharmacologic treatment options include the tricyclic antidepressant clomipramine and the selective serotonin reuptake inhibitors (SSRIs) citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. These have all shown benefit in acute treatment trials; clomipramine, fluvoxamine, fluoxetine, and sertraline have also demonstrated benefit in long-term treatment trials (at least 24 weeks), and clomipramine, sertraline, and fluvoxamine have United States Food and Drug Administration approvals for use in children and adolescents. Available treatment guidelines recommend first-line use of an SSR1 (ie, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) in preference to clomipramine, due to the latter's less favorable adverse-event profile. Further, pharmacotherapy for a minimum of 1–2 years is recommended before very gradual withdrawal may be considered.

Type
Academic Supplement
Information
CNS Spectrums , Volume 8 , supplement S1: Recommendations for the Long-Term Treatment of Anxiety Disorders , August 2003 , pp. 7 - 16
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Kramer, H, Sprenger, J. Malleus Makficarum. London, England: Pushkin Press; 1951.Google Scholar
2.Shakespeare, W. MacBeth. Act 5, scene 1, lines 32–34.Google Scholar
3.Robins, LN, Helzer, JE, Weissman, MM, et al.Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41:949–958.CrossRefGoogle ScholarPubMed
4.Weissman, MM, Bland, RC, Canino, GJ, et al.The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry. 1994;55(suppl):5–10.Google ScholarPubMed
5.Kessler, RC, McGonagle, KA, Zhao, S, et al.Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.CrossRefGoogle ScholarPubMed
6.Rasmussan, SA, Baer, L, Shera, D. Previous SRI treatment and efficacy of sertraline for OCD: combined analysis of 4 multicenter trials, [abstract]. Abstract presented at: Annual Meeting of the American Psychiatric Association; May 17–22, 1997; San Diego, CA.Google Scholar
7.Riddle, M. Obsessive-compulsive disorder in children and adolescents. Br J Psychiatry. 1998;(suppl):91–96.CrossRefGoogle ScholarPubMed
8.Fineberg, N. Refining treatment approaches in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1996;11(suppl 5):13–22.CrossRefGoogle ScholarPubMed
9.Sasson, Y, Zohar, J, Chopra, M, Lustig, M, Iancu, I, Hendler, T. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry. 1997;58(suppl 12):7–10.Google ScholarPubMed
10.Rauch, SL, Whalen, PJ, Curran, T, et al.Probing striato-thalamic function in obsessive-compulsive disorder and Tourette syndrome using neuroimaging methods. Adv Neurol. 2001;85:207–224.Google ScholarPubMed
11.Zohar, J, Mueller, EA, Insel, TR, Zohar-Kadouch, RC, Murphy, DL. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry. 1987;44:946–951.CrossRefGoogle ScholarPubMed
12.McDougle, CJ, Goodman, WK, Price, LH, et al.Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1990;147:652–654.Google ScholarPubMed
13.McDougle, CJ, Barr, LC, Goodman, WK, Price, LH. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinobgy. 1999;24:1–24.CrossRefGoogle ScholarPubMed
14.Leonard, HL, Swedo, SE, Garvey, M, et al.Postinfectious and other forms of obsessive-compulsive disorder. Child Adolesc Psychiatr Clin N Am. 1999;8:497–511.CrossRefGoogle ScholarPubMed
15.Zohar, J, Zohar-Kadouch, RC, Kindler, S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs. 1992;43:210–218.CrossRefGoogle ScholarPubMed
16.Thoren, P, Asberg, M, Bertilsson, L, Mellstrom, B, Sjoqvist, F, Traskman, L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry. 1980;37:1289–1294.CrossRefGoogle ScholarPubMed
17.Flament, MF, Rapoport, JL, Murphy, DL, Berg, CJ, Lake, CR. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry. 1987;44:219–225.CrossRefGoogle ScholarPubMed
18.Marazziti, D, Hollander, E, Lensi, P, Ravagli, S, Cassano, GB. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res. 1992;42:41–51.CrossRefGoogle ScholarPubMed
19.Marazziti, D, Pfanner, C, Palego, L, et al.Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine. Pharmacopsychiatry. 1997;30:245–249.CrossRefGoogle ScholarPubMed
20.Hollander, E, Kwon, JH, Stein, DJ, Broatch, J, Rowland, CT, Himelein, CA. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry. 1996;57(suppl 8):3–6.Google ScholarPubMed
21.Saxena, S, Wang, D, Bystritsky, A, Baxter, LR Jr.Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996;57:303–306.Google ScholarPubMed
22.Hollander, E, Broatch, J, Himelein, C. The economic burden of OCD [abstract]. Curr Opin Psychiatry. 1999;12(suppl 1):116.Google Scholar
23.The International Classification of Diseases. 10th revision. Geneva, Switzerland: World Health Organization; 1992.Google Scholar
24.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
25.Black, DW, Goldstein, RB, Noyes, R Jr., Blum, N. Psychiatric disorders in relatives of probands with obsessive-compulsive disorder and co-morbid major depression or generalized anxiety. Psychiatr Genet. 1995;5:37–41.CrossRefGoogle ScholarPubMed
26.Pigott, TA, L'Heureux, F, Dubbert, B, Bernstein, S, Murphy, DL. Obsessive compulsive disorder: comorbid conditions. J Clin Psychiatry. 1994;55(suppl):15–27.Google ScholarPubMed
27.Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry. 1991;48:730–738.CrossRefGoogle Scholar
28.Lydiard, RB, Brawman-Mintzer, O, Ballenger, JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol. 1996;64:660–668.CrossRefGoogle ScholarPubMed
29.Hoehn-Saric, R, Ninan, P, Black, DW, et al.Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000;57:76–82.CrossRefGoogle ScholarPubMed
30.Pato, MT. Beyond depression: citalopram for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1999;14(suppl 2):S19–S26.Google ScholarPubMed
31.Marazziti, D, Dell'Osso, L, Gemignani, A, et al.Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol. 2001;16:215–219.CrossRefGoogle ScholarPubMed
32.Greist, JH, Jefferson, JW, Kobak, KA, Katzelnick, DJ, Serlin, RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995;52:53–60.CrossRefGoogle ScholarPubMed
33.Bisserbe, JC, Lane, RM, Flament, MF, et al.A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry. 1997;12:82–93.CrossRefGoogle ScholarPubMed
34.Freeman, CP, Trimble, MR, Deakin, JF, Stokes, TM, Ashford, JJ. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry. 1994;55:301–305.Google ScholarPubMed
35.Zohar, J, Judge, R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry. 1996;169:468–474.CrossRefGoogle ScholarPubMed
36.Milanfranchi, A, Ravagli, S, Lensi, P, Marazziti, D, Cassano, GB. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997;12:131–136.CrossRefGoogle ScholarPubMed
37.Montgomery, SA. Long-term management of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1996;11(suppl 5):23–29.CrossRefGoogle ScholarPubMed
38.Thoren, P, Asberg, M, Cronholm, B, Jornestedt, L, Traskman, L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry. 1980;37:1281–1285.CrossRefGoogle Scholar
39.Katz, RJ, DeVeaugh-Geiss, J, Landau, P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry. 1990;28:401–414.CrossRefGoogle ScholarPubMed
40.Tollefson, GD, Rampey, AH Jr., Potvin, JH, et al.A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559–567.CrossRefGoogle ScholarPubMed
41.Romano, S, Goodman, W, Tamura, R, Gonzales, J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001;21:46–52.CrossRefGoogle ScholarPubMed
42.Cottraux, J, Mollard, E, Bouvard, M, et al.A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1990;5:17–30.CrossRefGoogle ScholarPubMed
43.Mallya, GK, White, K, Waternaux, C, et al.Short- and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Ann Clin Psychiatry. 1992;4:77–80.CrossRefGoogle Scholar
44.Greist, JH, Jefferson, JW, Kobak, KA, et al.A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:57–65.CrossRefGoogle ScholarPubMed
45.Rasmussen, S, Hackett, E, DuBoff, E, et al.A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997;12:309–316.CrossRefGoogle ScholarPubMed
46.McDougle, CJ, Epperson, CN, Pelton, GH, Wasylink, S, Price, LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794–801.CrossRefGoogle ScholarPubMed
47.Goodman, WK, Londborg, PD, Lydiard, RB. Safety of sertraline in longterm OCD treatment: preliminary results of a multicenter study. Abstract presented at: Annual Meeting of the American Psychiatric Association; Washington, DC; May 15–20, 1999.Google Scholar
48.Tollefson, GD, Birkett, M, Koran, L, Genduso, L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry. 1994;55(suppl):69–76.Google ScholarPubMed
49.Koran, LM, Hackett, E, Rubin, A, Wolkow, R and Robinson, D. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry. 2002; 159:88–95.CrossRefGoogle ScholarPubMed
50.Bergeron, R, Ravindran, AV, Chaput, Y, et al.Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychofiharmacol. 2002;22:148–154.CrossRefGoogle ScholarPubMed
51.Pfanner, C, Marazziti, D, Dell'Osso, L, et al.Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol. 2000; 15:297–301.CrossRefGoogle ScholarPubMed
52.McDougle, CJ, Goodman, WK. Combination pharmacological treatment strategies. In: Hollander, E, Stein, D, eds. OCD: Diagnosis, Etiology and Treatments. New York, NY: Marcel Dekker; 1999;203–223.Google Scholar
53.Li, X, Jackson, WT, Baxter, LR. Risperidone vs. haloperidol augmentation in SRI refractory OCD: clinical and neuro-cognitive effects. Abstract presented at: 38th Annual Meeting of the American College Neuropsychopharmacology; December 12–16, 1999; Acapulco, Mexico;Google Scholar
54.Ravizza, L, Barzega, G, Bellino, S, Bogetto, F, Maina, G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull. 1996;32:167–173.Google ScholarPubMed
55.McDougle, CJ, Goodman, WK, Leckman, JF, Lee, NC, Heninger, GR, Price, LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302–308.CrossRefGoogle ScholarPubMed
56.Sasson, Y, Bermanzohn, P, Zohar, J. Treatment of obsessive-compulsive syndromes in schizophrenia. CNS Spectr. 1997;2:34–35.CrossRefGoogle Scholar
57.Meyer, V. Modification of expectations in cases with obsessional rituals. Behav Res Ther. 1966;4:273–280.CrossRefGoogle ScholarPubMed
58.Kobak, KA, Greist, JH, Jefferson, JW, Katzelnick, DJ, Henk, HJ. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl). 1998;136:205–216.CrossRefGoogle ScholarPubMed
59.Neziroglu, F, Hsia, C, Yaryura-Tobias, JA. Behavioral, cognitive, and family therapy for obsessive-compulsive and related disorders. Psychiatr Clin North Am. 2000;23:657–670.CrossRefGoogle ScholarPubMed
60.Greist, JH. Behavior therapy for obsessive compulsive disorder. J Clin Psychiatry. 1994;55(suppl):60–68.Google ScholarPubMed
61.O'Connor, K, Todorov, C, Robillard, S, Borgeat, F, Brault, M. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study. Can J Psychiatry. 1999;44:64–71.CrossRefGoogle ScholarPubMed
62.McKay, D. A maintenance program for obsessive-compulsive disorder using exposure with response prevention: 2-year follow-up. Behav Res Ther. 1997;35:367–369.CrossRefGoogle Scholar
63.Christensen, H, Hadzi-Pavlovic, D, Andrews, G, Mattick, R. Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1987;55:701–711.CrossRefGoogle ScholarPubMed
64.Cox, BJ, Swinson, RP, Morrison, B, Lee, PS. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. J Behav Ther Exp Psychiatry. 1993;24:149–153.CrossRefGoogle ScholarPubMed
65.van Oppen, P, de Haan, E, van Balkom, AJ, Spinhoven, P, Hoogduin, K, van Dyck, R. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behav Res Ther. 1995;33:379–390.CrossRefGoogle ScholarPubMed
66.Alonso, P, Menchon, JM, Pifarre, J, et al.Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry. 2001; 62:535–540.CrossRefGoogle ScholarPubMed
67. Treatment of obsessive-compulsive disorder. The Expert Consensus Panel for obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(suppl 4):2–72.Google Scholar